logo
Plus   Neg
Share
Email

Jacobs Engineering Turns To Profit In Q4; Sees Growth In FY20 Adj. EBITDA

Professional services provider Jacobs Engineering Group, Inc. (JEC) on Monday reported that its fourth-quarter net earnings attributable to the company were $142.32 million, compared to last year's loss of $37.54 million. Earnings per share were $1.04, compared to loss of $0.26 last year.

Net earnings from continuing operations were $22 million or $0.16 per share, compared to loss of $77 million or $0.54 per share a year ago.

Adjusted net earnings from continuing operations were $201 million or $1.48 per share, compared to prior year's $165 million or $1.14 per share.

On average, analysts polled by Thomson Reuters expected earnings of $1.32 per share. Analysts' estimates typically exclude special items.

Revenue for the period grew 13 percent to $3.4 billion from $3.0 billion last year. Net Revenue increased 15 percent to $2.7 billion from prior year's $2.3 billion.

Looking ahead, for fiscal 2020, the company expects adjusted EBITDA of $1.05 billion to $1.15 billion, representing double-digit growth for adjusted EBITDA and earnings per share from the year 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT